Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab to Inhibit HLA Antibodies in Renal Allograft Recipients
NCT00261547Phase 2Withdrawn
- Sponsor
- Massachusetts General Hospital
- Start
- Dec 2005
- Primary completion
- Nov 2007
- Modality
- Monoclonal Antibodies
01
Overview
Phase 2, open-label, single-arm trial of rituximab in chronic rejection and Renal Insufficiency (RI), sponsored by Massachusetts General Hospital. Primary endpoints: Negative Donor Specific Antibodies at 12 months and Lack of C4d deposition in peritubular capillary at 12 months. Planned start Dec 2005; status: withdrawn.
02
Drugs
rituximab
03
Conditions
chronic rejectionRenal Insufficiency (RI)
Beyond the preview
Go deeper on NCT00261547.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00261547.